Newron Pharmaceuticals S.p.A

Newron Pharmaceuticals S.p.A was founded in 1999 and is headquartered in Bresso, near Milan, Italy. It also has a subsidiary in Morristown, NJ, USA. The company has a market cap of about $1.5B as of May 2023 and is listed on the SIX Swiss Exchange, the primary market of the Düsseldorf Stock Exchange, and on XETRA.

Newron Pharmaceuticals S.p.A's vision is to deliver innovative treatments to improve the quality of life for patients with CNS disorders. It has a strong pipeline of promising treatments, including one marketed product and wholly-owned product candidates in clinical development.

Newron Pharmaceuticals S.p.A's product is Xadago®, a once-daily oral medication for Parkinson's disease that was approved by the European Commission in 2015 and by the US Food and Drug Administration in 2017. It is also approved in several other countries, such as Japan, Australia, Canada and Brazil.

The company's main project is Evenamide, a potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. It is currently in phase III clinical trials and has received Fast Track designation from the US FDA. Newron Pharmaceuticals S.p.A's other project is ralfinamide, a sodium channel blocker for patients with specific rare pain indications, such as lumbosacral radicular pain and neuropathic pain associated with Fabry disease. It is currently in phase II clinical trials.

Foundation: 1999

Headquarters: Bresso, Italy

Website: https://www.newron.com/